Evidence map›Paper›PMID 34399583›Full record

ReviewStroke2021

Stroke Genetics: Turning Discoveries into Clinical Applications.

Martin Dichgans, Nathalie Beaufort, Stephanie Debette, Christopher D Anderson

Abstract readReview
In one paragraph

Review in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Genetics in Ischemic Stroke: Current Perspectives and Future Directions.Journal of cardiovascular development and disease · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. The Future of Ischemic Stroke Diagnosis and a Review of Underrecognized Ischemic Stroke Etiologies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martin DichgansInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Germany (M.D., N.B.).
Nathalie BeaufortInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Germany (M.D., N.B.).
Stephanie DebetteUniversity of Bordeaux, INSERM, Bordeaux Population Health Center, UMR1219, Team VINTAGE, France (S.D.).
Christopher D AndersonDepartment of Neurology, Brigham and Women's Hospital, Boston, MA (C.D.A.).

Funding

Ethnic/Racial Variation in Intracerebral Hemorrhage (ERICH)U01NS069763 · NINDS · UNIVERSITY OF CINCINNATI · PI ANDERSON, CHRISTOPHER DAVID, DEMEL, STACIE · 2010 to 2024
$34.2M
Sequencing Annotation and Functional Analysis in Risk of Intracerebral HemorrhageR01NS103924 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDERSON, CHRISTOPHER DAVID · 2018 to 2022
$3.4M
NINDS NIH HHS R01 NS103924NINDS NIH HHS U01 NS069763
6 · The paper itself

Abstract

The field of medical and population genetics in stroke is moving at a rapid pace and has led to unanticipated opportunities for discovery and clinical applications. Genome-wide association studies have highlighted the role of specific pathways relevant to etiologically defined subtypes of stroke and to stroke as a whole. They have further offered starting points for the exploration of novel pathways and pharmacological strategies in experimental systems. Mendelian randomization studies continue to provide insights in the causal relationships between exposures and outcomes and have become a useful tool for predicting the efficacy and side effects of drugs. Additional applications that have emerged from recent discoveries include risk prediction based on polygenic risk scores and pharmacogenomics. Among the topics currently moving into focus is the genetics of stroke outcome. While still at its infancy, this field is expected to boost the development of neuroprotective agents. We provide a brief overview on recent progress in these areas.

Indexed as

Genetic Predisposition to DiseaseHumansMendelian Randomization AnalysisPharmacogeneticsPolymorphism, Single NucleotideRisk FactorsStrokeblood pressurecardiovascular diseasecoronary artery diseasegeneticslipoprotein

Identifiers

PMID34399583
PMCPMC8384143

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.